Clinical Trial Search

Phase 3 N=1,574 A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

SARS-CoV-2 Infection · COVID-19

Primary: Geometric Mean Ratios (GMRs) of Full-Length S-Binding Immunoglobulin G (IgG) Concentrations Between Individual US Lots 1, 2, and 3 at 1 Month After Dose 2: Primary Study…

BioNTech SE Results Dec 2022 0.1% serious AE View details

Phase 3 N=63 Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Neuroendocrine Tumors

Primary: Sensitivity of 64Cu-DOTATATE PET-CT Imaging for Detection of Somatostatin Receptor Positive SSTR (+) Tumor — 30; 3 Participants

Radiomedix, Inc. Results Dec 2022 0.0% serious AE View details

Phase 3 N=215 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

Cataract

Primary: Anterior Chamber Cell Grade — 38; 7 Participants

Salvat Results Dec 2022 1.4% serious AE View details

Phase 3 N=195 A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis

Primary: Total Symptom Score (TSS) Response Rate at Week 24 — 24.62; 9.23 Percentage of participants — p=0.0095

Sierra Oncology LLC - a GSK company Results Dec 2022 34.4% serious AE View details

Phase 3 N=354 Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Primary: Percentage of Participants Achieving Clinical Remission — 24.8; 15.2 Percentage of participants — p==0.026

Arena Pharmaceuticals Results Dec 2022 2.3% serious AE View details

Phase 3 N=910 Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

COVID-19

Primary: A Composite of Either Severe COVID-19 or Death From Any Cause Through Day 29 — 18; 37 Participants — p=0.010

AstraZeneca Results Dec 2022 12.3% serious AE View details

Phase 3 N=433 Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Primary: Percentage of Participants Achieving Clinical Remission at Week 12 — 27.0; 7.4 Percentage of participants — p=<0.001

Arena Pharmaceuticals Results Dec 2022 6.7% serious AE View details

Phase 3 N=136 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

Binge-eating Disorder · Obesity

Primary: Binge Eating Frequency (Continuous) — 9.90; 7.63; 3.30; 1.97 binge-eating episodes per month — p=0.0001

Yale University Results Dec 2022 0.9% serious AE View details

Phase 3 N=5,197 Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

COVID-19

Primary: Number of Participants With First Case of SARS-CoV-2 RT-PCR-positive Symptomatic Illness — 8; 17; 12; 34 Participants — p=<0.001

AstraZeneca Results Dec 2022 6.8% serious AE View details

Phase 3 N=1,020 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Psoriasis

Primary: The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA…

Bristol-Myers Squibb Results Dec 2022 1.7% serious AE View details

Phase 3 N=783 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Melanoma

Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) — 27.7; 36.0 Percentage of participants — p=0.0311

Bristol-Myers Squibb Results Dec 2022 43.3% serious AE View details

Phase 3 N=2,629 Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women

HIV Infections

Primary: Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. — 71; 97 Participants

International Partnership for Microbicides, Inc. Results Dec 2022 9.4% serious AE View details

Phase 3 N=113 A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Motor OFF Episodes Associated With Parkinson's Disease

Primary: Change From Pre-dose to 90 Mins. Post-dose in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score After 4 Weeks of Dosing in Each…

Sumitomo Pharma America, Inc. Results Dec 2022 0.9% serious AE View details

Phase 3 N=289 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

Psoriasis

Primary: Percentage of Participants With a Modified sPGA-G Response at Week 16 — 19.5; 39.6 Percentage of participants — p=0.0003

Amgen Results Dec 2022 1.4% serious AE View details

Phase 3 N=73 A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor · Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor · Hemophilia A

Primary: Model-Based Annualized Bleed Rate for Treated Bleeds — 0.9 Treated bleeds per year

Hoffmann-La Roche Results Dec 2022 11.1% serious AE View details